Raffi Minasian, MD
Nephrology · Glendale, CANPI 1306860465
Payments from drug & device makers
Across 663 payments — averaging $2323.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$640K
- GSK$302K
- AstraZeneca$184K
- Travere Therapeutics, Inc.$154K
- Akebia Therapeutics Inc$104K
- Merck$73K
- plus $82K from 23 others
What the payments were for
- Consulting fees$580%
- Speaking & faculty fees$7,04951%
- Food & beverage$6,53447%
- Education$2242%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 109 | $639,740 |
| GSK | 51 | $301,632 |
| AstraZeneca(2 entities) | 69 | $184,470 |
| Travere Therapeutics, Inc. | 126 | $154,415 |
| Akebia Therapeutics Inc | 115 | $104,424 |
| Merck | 3 | $73,321 |
| Novartis | 11 | $43,114 |
| Bayer | 26 | $23,675 |
| Aurinia Pharma U.S., Inc. | 8 | $7,671 |
| Amgen(2 entities) | 40 | $4,858 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $963 |
| Otsuka America Pharmaceutical, Inc. | 25 | $446 |
| Mallinckrodt Hospital Products Inc. | 11 | $289 |
| Novo Nordisk | 11 | $206 |
| Fresenius USA Marketing, Inc. | 11 | $176 |
| Vifor Pharma, Inc. | 9 | $168 |
| Sanofi-aventis U.S. LLC | 7 | $159 |
| OPKO Pharmaceuticals, LLC | 8 | $136 |
| La Jolla Pharmaceutical Company | 1 | $117 |
| Kowa Pharmaceuticals America, Inc. | 3 | $102 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $101 |
| Mallinckrodt Enterprises LLC | 3 | $76 |
| Gastroklenz, Inc. DBA Cloudcath | 1 | $65 |
| Ardelyx, Inc. | 2 | $35 |
| Nuwellis, Inc. | 1 | $34 |
| Calliditas Therapeutics US Inc. | 1 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Amarin Pharma, Inc. | 1 | $21 |
| AbbVie | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,540,495 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 286 | $243,655 |
| JynarqueTolvaptan | 12 | $241,612 |
| KerendiaFinerenone | 229 | $230,099 |
| VelphoroSucroferric Oxyhydroxide | 63 | $226,062 |
| OzempicSemaglutide | 208 | $220,750 |
| LokelmaSodium Zirconium Cyclosilicate | 222 | $197,918 |
| ProcritEpoetin Alfa | 81 | $167,294 |
| JardianceEmpagliflozin | 161 | $140,848 |
| RybelsusSemaglutide | 97 | $121,794 |
| TrulicityDulaglutide | 90 | $117,934 |
| Sevelamer Hcl | 73 | $108,129 |
| MounjaroTirzepatide | 88 | $102,857 |
| VeltassaPatiromer Calcium Sorbitex | 84 | $92,696 |
| Lanthanum Carbonate | 39 | $80,557 |
| XphozahTenapanor Hcl | 25 | $78,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $184,470 | $441,572508 claims |
| Novo NordiskOzempic, Rybelsus | $206 | $342,544305 claims |
| Otsuka America Pharmaceutical, Inc.Jynarque | $446 | $241,61212 claims |
| BayerKerendia | $23,675 | $230,099229 claims |
| Fresenius USA Marketing, Inc.Velphoro | $176 | $226,06263 claims |
| MerckJanuvia | $73,321 | $63,22969 claims |
| Sanofi-aventis U.S. LLCRenvela | $159 | $39,85829 claims |
| Akebia Therapeutics IncAuryxia | $104,424 | $39,50031 claims |
| AbbVieLinzess | $18 | $38,22154 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $136 | $37,75415 claims |
| AmgenProlia | $4,858 | $37,37922 claims |
| NovartisEntresto | $43,114 | $33,55728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,341 nephrology providers in California.
Other nephrology in Glendale
- Sam DaneshvariGlendale$1.1M
- Artashes PatrikyanGlendale$950K
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.